Scott D Solomon1, Brian Claggett2, Eldrin F Lewis2, Akshay Desai2, Inder Anand3, Nancy K Sweitzer4, Eileen O'Meara5, Sanjiv J Shah6, Sonja McKinlay7, Jerome L Fleg8, George Sopko8, Bertram Pitt9, Marc A Pfeffer2. 1. Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115, USA ssolomon@rics.bwh.harvard.edu. 2. Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115, USA. 3. Minneapolis VA Hospital, Minneapolis, MN, USA. 4. University of Arizona, Tuscon, AZ, USA. 5. Montreal Heart Institute, Montreal, Canada. 6. Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 7. New England Research Institute, Watertown, MA, USA. 8. National Heart, Lung and Blood Institute, Bethesda, MD, USA. 9. University of Michigan, Ann Arbor, MI, USA.
Abstract
AIMS: While mineralocorticoid receptor antagonists (MRAs) have been shown to benefit patients with reduced left ventricular ejection fraction (LVEF), spironolactone did not reduce the primary endpoint of cardiovascular death, heart failure hospitalization, or aborted cardiac arrest in patients with heart failure with preserved ejection fraction (HFpEF) in the TOPCAT trial, which enrolled patients with LVEF of 45% or greater. We utilized data from TOPCAT to assess the relationship between LVEF as well as outcomes and efficacy of spironolactone. METHODS AND RESULTS: We assessed differences in baseline characteristics and outcomes across LVEF categories in 3444 patients with HFpEF, and determined whether LVEF modified the treatment effect of spironolactone. Ejection fraction ranged from 44 to 85%. Patients with higher ejection fraction were older, more likely to be female, less likely to have a history of myocardial infarction, and more likely to have a history of hypertension and diabetes. The incidence of the primary endpoint and cardiovascular death was highest in patients at the lower end of the ejection fraction spectrum. Ejection fraction modified the spironolactone treatment effect, particularly in the patients enrolled in the Americas, for the primary outcome (P = 0.046) and for heart failure hospitalization (P = 0.039), with stronger estimated benefits of spironolactone at the lower end of the ejection fraction spectrum with respect to the primary endpoint (LVEF <50%: HR 0.72, 95% CI 0.50, 1.05; LVEF ≥60%: HR 0.97, 95% CI 0.76, 1.23) and heart failure hospitalization (LVEF <50%: HR 0.76, 95% CI 0.46, 1.27; LVEF ≥60%: HR 0.98, 95% CI 0.74, 1.30). CONCLUSION: In patients with HFpEF enrolled inTOPCAT, patient characteristics and outcomes varied substantially by LVEF. The potential efficacy of spironolactone was greatest at the lower end of the LVEF spectrum. CLINICALTRIALSGOV NUMBER: NCT00094302. Published on behalf of the European Society of Cardiology. All rights reserved.
RCT Entities:
AIMS: While mineralocorticoid receptor antagonists (MRAs) have been shown to benefit patients with reduced left ventricular ejection fraction (LVEF), spironolactone did not reduce the primary endpoint of cardiovascular death, heart failure hospitalization, or aborted cardiac arrest in patients with heart failure with preserved ejection fraction (HFpEF) in the TOPCAT trial, which enrolled patients with LVEF of 45% or greater. We utilized data from TOPCAT to assess the relationship between LVEF as well as outcomes and efficacy of spironolactone. METHODS AND RESULTS: We assessed differences in baseline characteristics and outcomes across LVEF categories in 3444 patients with HFpEF, and determined whether LVEF modified the treatment effect of spironolactone. Ejection fraction ranged from 44 to 85%. Patients with higher ejection fraction were older, more likely to be female, less likely to have a history of myocardial infarction, and more likely to have a history of hypertension and diabetes. The incidence of the primary endpoint and cardiovascular death was highest in patients at the lower end of the ejection fraction spectrum. Ejection fraction modified the spironolactone treatment effect, particularly in the patients enrolled in the Americas, for the primary outcome (P = 0.046) and for heart failure hospitalization (P = 0.039), with stronger estimated benefits of spironolactone at the lower end of the ejection fraction spectrum with respect to the primary endpoint (LVEF <50%: HR 0.72, 95% CI 0.50, 1.05; LVEF ≥60%: HR 0.97, 95% CI 0.76, 1.23) and heart failure hospitalization (LVEF <50%: HR 0.76, 95% CI 0.46, 1.27; LVEF ≥60%: HR 0.98, 95% CI 0.74, 1.30). CONCLUSION: In patients with HFpEF enrolled in TOPCAT, patient characteristics and outcomes varied substantially by LVEF. The potential efficacy of spironolactone was greatest at the lower end of the LVEF spectrum. CLINICALTRIALSGOV NUMBER: NCT00094302. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart Journal: J Am Soc Echocardiogr Date: 2005-12 Impact factor: 5.251
Authors: Marc A Pfeffer; Brian Claggett; Susan F Assmann; Robin Boineau; Inder S Anand; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; John F Heitner; Eldrin F Lewis; Eileen O'Meara; Jean-Lucien Rouleau; Jeffrey L Probstfield; Tamaz Shaburishvili; Sanjiv J Shah; Scott D Solomon; Nancy K Sweitzer; Sonja M McKinlay; Bertram Pitt Journal: Circulation Date: 2014-11-18 Impact factor: 29.690
Authors: Scott D Solomon; Nagesh Anavekar; Hicham Skali; John J V McMurray; Karl Swedberg; Salim Yusuf; Christopher B Granger; Eric L Michelson; Duolao Wang; Stuart Pocock; Marc A Pfeffer Journal: Circulation Date: 2005-12-05 Impact factor: 29.690
Authors: Bertram Pitt; Marc A Pfeffer; Susan F Assmann; Robin Boineau; Inder S Anand; Brian Claggett; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Brian Harty; John F Heitner; Christopher T Kenwood; Eldrin F Lewis; Eileen O'Meara; Jeffrey L Probstfield; Tamaz Shaburishvili; Sanjiv J Shah; Scott D Solomon; Nancy K Sweitzer; Song Yang; Sonja M McKinlay Journal: N Engl J Med Date: 2014-04-10 Impact factor: 91.245
Authors: Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin Journal: N Engl J Med Date: 2003-03-31 Impact factor: 91.245
Authors: Salim Yusuf; Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren Journal: Lancet Date: 2003-09-06 Impact factor: 79.321
Authors: Javed Butler; Gregg C Fonarow; Michael R Zile; Carolyn S Lam; Lothar Roessig; Erik B Schelbert; Sanjiv J Shah; Ali Ahmed; Robert O Bonow; John G F Cleland; Robert J Cody; Ovidiu Chioncel; Sean P Collins; Preston Dunnmon; Gerasimos Filippatos; Martin P Lefkowitz; Catherine N Marti; John J McMurray; Frank Misselwitz; Savina Nodari; Christopher O'Connor; Marc A Pfeffer; Burkert Pieske; Bertram Pitt; Giuseppe Rosano; Hani N Sabbah; Michele Senni; Scott D Solomon; Norman Stockbridge; John R Teerlink; Vasiliki V Georgiopoulou; Mihai Gheorghiade Journal: JACC Heart Fail Date: 2014-04 Impact factor: 12.035
Authors: Sanjiv J Shah; Dalane W Kitzman; Barry A Borlaug; Loek van Heerebeek; Michael R Zile; David A Kass; Walter J Paulus Journal: Circulation Date: 2016-07-05 Impact factor: 29.690
Authors: Oliver Riedel; C Ohlmeier; D Enders; A Elsässer; D Vizcaya; A Michel; S Eberhard; N Schlothauer; J Berg; E Garbe Journal: Clin Res Cardiol Date: 2018-02-05 Impact factor: 5.460
Authors: Senthil Selvaraj; Brian Claggett; Sanjiv J Shah; Inder Anand; Jean L Rouleau; Eileen O'Meara; Akshay S Desai; Eldrin F Lewis; Bertram Pitt; Nancy K Sweitzer; James C Fang; Marc A Pfeffer; Scott D Solomon Journal: Circ Heart Fail Date: 2018-11 Impact factor: 8.790
Authors: Vijeta Bhambhani; Jorge R Kizer; Joao A C Lima; Pim van der Harst; Hossein Bahrami; Matthew Nayor; Christopher R de Filippi; Danielle Enserro; Michael J Blaha; Mary Cushman; Thomas J Wang; Ron T Gansevoort; Caroline S Fox; Hanna K Gaggin; Willem J Kop; Kiang Liu; Ramachandran S Vasan; Bruce M Psaty; Douglas S Lee; Frank P Brouwers; Hans L Hillege; Traci M Bartz; Emelia J Benjamin; Cheeling Chan; Matthew Allison; Julius M Gardin; James L Januzzi; Daniel Levy; David M Herrington; Wiek H van Gilst; Alain G Bertoni; Martin G Larson; Rudolf A de Boer; John S Gottdiener; Sanjiv J Shah; Jennifer E Ho Journal: Eur J Heart Fail Date: 2017-12-11 Impact factor: 15.534
Authors: Fabiana G Marcondes-Braga; Lídia Ana Zytynski Moura; Victor Sarli Issa; Jefferson Luis Vieira; Luis Eduardo Rohde; Marcus Vinícius Simões; Miguel Morita Fernandes-Silva; Salvador Rassi; Silvia Marinho Martins Alves; Denilson Campos de Albuquerque; Dirceu Rodrigues de Almeida; Edimar Alcides Bocchi; Felix José Alvarez Ramires; Fernando Bacal; João Manoel Rossi Neto; Luiz Claudio Danzmann; Marcelo Westerlund Montera; Mucio Tavares de Oliveira Junior; Nadine Clausell; Odilson Marcos Silvestre; Reinaldo Bulgarelli Bestetti; Sabrina Bernadez-Pereira; Aguinaldo F Freitas; Andréia Biolo; Antonio Carlos Pereira Barretto; Antônio José Lagoeiro Jorge; Bruno Biselli; Carlos Eduardo Lucena Montenegro; Edval Gomes Dos Santos Júnior; Estêvão Lanna Figueiredo; Fábio Fernandes; Fabio Serra Silveira; Fernando Antibas Atik; Flávio de Souza Brito; Germano Emílio Conceição Souza; Gustavo Calado de Aguiar Ribeiro; Humberto Villacorta; João David de Souza Neto; Livia Adams Goldraich; Luís Beck-da-Silva; Manoel Fernandes Canesin; Marcelo Imbroinise Bittencourt; Marcely Gimenes Bonatto; Maria da Consolação Vieira Moreira; Mônica Samuel Avila; Otavio Rizzi Coelho Filho; Pedro Vellosa Schwartzmann; Ricardo Mourilhe-Rocha; Sandrigo Mangini; Silvia Moreira Ayub Ferreira; José Albuquerque de Figueiredo Neto; Evandro Tinoco Mesquita Journal: Arq Bras Cardiol Date: 2021-06 Impact factor: 2.000